| P50 | author | Stephanie Shiau | Q57542015 |
| | Louise Kuhn | Q61451544 |
| | Renate Strehlau | Q88293864 |
| | Ashraf Coovadia | Q90796868 |
| P2093 | author name string | Jonathan J Kaufman | |
| | Donald J McMahon | |
| | Michael T Yin | |
| | Faeezah Patel | |
| | Stephen M Arpadi | |
| | Ndileka Mbete | |
| P2860 | cites work | Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review | Q22242702 |
| | Variations in pattern of pubertal changes in girls | Q24569515 |
| | Variations in the Pattern of Pubertal Changes in Boys | Q24569516 |
| | TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src | Q28142620 |
| | Normal bone anatomy and physiology | Q28299969 |
| | Calcium accretion in girls and boys during puberty: a longitudinal analysis | Q30969017 |
| | Interpretation of whole body dual energy X-ray absorptiometry measures in children: comparison with peripheral quantitative computed tomography | Q31078331 |
| | Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects | Q33191037 |
| | Analysis of bone mineral content in horizontally HIV-infected children naïve to antiretroviral treatment | Q33220907 |
| | A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children | Q33226944 |
| | Childhood fractures are associated with decreased bone mass gain during puberty: an early marker of persistent bone fragility? | Q33239087 |
| | Association between bone mass and fractures in children: a prospective cohort study | Q33255693 |
| | Bone mass accretion rates in pre- and early-pubertal South African black and white children in relation to habitual physical activity and dietary calcium intakes | Q33286181 |
| | Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children | Q33526749 |
| | Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. | Q33532361 |
| | Incident fractures in HIV-infected individuals: a systematic review and meta-analysis | Q33648297 |
| | Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study | Q34019655 |
| | Bone mineral density in children and adolescents with perinatal HIV infection | Q34150394 |
| | Peak bone mass | Q34188920 |
| | Plasma levels of soluble CD14 independently predict mortality in HIV infection | Q34764002 |
| | Effects of HIV infection and antiretroviral therapy with ritonavir on induction of osteoclast-like cells in postmenopausal women | Q35055196 |
| | A frailty-related phenotype before HAART initiation as an independent risk factor for AIDS or death after HAART among HIV-infected men | Q35166235 |
| | Noncanonical Wnt signaling promotes osteoclast differentiation and is facilitated by the human immunodeficiency virus protease inhibitor ritonavir | Q35675377 |
| | Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy | Q35945312 |
| | Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial | Q35965440 |
| | Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial | Q35965722 |
| | Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children | Q36238419 |
| | Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial | Q36306986 |
| | Changing Trends in Complications and Mortality Rates Among US Youth and Young Adults With HIV Infection in the Era of Combination Antiretroviral Therapy | Q36311433 |
| | Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy | Q36456570 |
| | Bone mineral acquisition during adolescence and early adulthood: a study in 574 healthy females 10-24 years of age. | Q36807530 |
| | The protease inhibitors and HIV-associated bone loss | Q36818259 |
| | Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis | Q36833511 |
| | Decreased Vigorous Physical Activity in School-Aged Children with Human Immunodeficiency Virus in Johannesburg, South Africa | Q36839977 |
| | WNT/beta-catenin signaling is involved in regulation of osteoclast differentiation by human immunodeficiency virus protease inhibitor ritonavir: relationship to human immunodeficiency virus-linked bone mineral loss | Q37073777 |
| | Physical activity and sedentary behavior in an ethnically diverse group of South african school children | Q37709299 |
| | 2013 Pediatric Position Development Conference: executive summary and reflections | Q38198382 |
| | HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts. | Q40164984 |
| | HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity | Q40510848 |
| | HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. | Q40668951 |
| | The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling | Q41062466 |
| | Bone mass in children and adolescents infected with human immunodeficiency virus | Q42268531 |
| | Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. | Q42970792 |
| | Select HIV protease inhibitors alter bone and fat metabolism ex vivo | Q43950615 |
| | Altered bone metabolism in children infected with human immunodeficiency virus | Q44554942 |
| | Predictors of bone mineral density in human immunodeficiency virus-1 infected children | Q45424259 |
| | Changed bone status in human immunodeficiency virus type 1 (HIV-1) perinatally infected children is related to low serum free IGF-I. | Q45540330 |
| | Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children | Q45699979 |
| | Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. | Q45729264 |
| | Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services | Q46692083 |
| | Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection | Q46807661 |
| | Bone mineral content is lower in prepubertal HIV-infected children | Q47616407 |
| | Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10). | Q51767759 |
| | Bone Quality in Perinatally HIV-Infected Children: Role of Age, Sex, Growth, HIV Infection, and Antiretroviral Therapy | Q61508463 |
| | A theoretical analysis of the relative influences of peak BMD, age-related bone loss and menopause on the development of osteoporosis | Q73773561 |
| | Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy | Q74575738 |
| | HIV type 1 alters mesenchymal stem cell differentiation potential and cell phenotype ex vivo | Q85170670 |
| | HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: beneficial effect of pravastatin | Q86997373 |
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | South Africa | Q258 |
| | efavirenz | Q422645 |
| P304 | page(s) | 2459-2467 | |
| P577 | publication date | 2016-10-01 | |
| P1433 | published in | AIDS | Q4651863 |
| P1476 | title | Efavirenz is associated with higher bone mass in South African children with HIV | |
| P478 | volume | 30 | |